Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
Precision oncology has advanced across major cancers, yet inequitable biomarker testing, reimbursement, and infrastructure constrain real-world therapeutic access.
Global cancer burden is rising, with marked regional disparities driven by screening access, treatment capacity, socioeconomic development, and modifiable risk exposures.
Obesity and T2DM promote endometrial carcinogenesis via metabolic-endocrine dysregulation; metformin shows mechanistic promise but lacks definitive preventive evidence.
Cushing’s syndrome diagnosis requires stepwise biochemical confirmation, etiologic localization, and treatment-directed classification to prevent misdiagnosis and optimize outcomes.
ACC prognosis relies on ENSAT stage, resection status, Ki-67, histopathology, and molecular heterogeneity; predictive mitotane biomarkers remain unvalidated.
AI-assisted dermoscopy shows dermatologist-level sensitivity for melanoma detection, but requires broader prospective validation across diverse populations and clinical workflows.
Evidence supports immunotherapy-first sequencing for BRAF V600E-mutant advanced melanoma, reserving BRAF/MEK inhibitors for urgent cytoreduction.
Alcohol increases site-specific cancer risk through dose-dependent carcinogenic mechanisms, with no safe threshold best supported for breast and esophageal cancers.
Alcohol promotes dose-dependent carcinogenesis through acetaldehyde genotoxicity, oxidative stress, and epigenetic dysregulation, supporting prevention-focused clinical and policy interventions.
A comparative review of CAR-T therapy and bispecific antibodies in relapsed or refractory non-Hodgkin lymphoma.
PD-L1 upregulation, Treg infiltration, and MDSC accumulation jointly drive immune escape in cervical cancer.
9vHPV vaccination demonstrates robust immunogenicity, favorable safety, and sustained preventive efficacy across diverse age groups.
Nanocarrier and CED strategies offer promising but still clinically evolving approaches to improve drug delivery in malignant gliomas.
CAR-T–ICI combinations offer a rational GBM strategy, but durable efficacy and safety require prospective validation.
Molecularly guided therapies are reshaping brain cancer research but remain clinically constrained.
CARVYKTI is a BCMA-directed CAR-T therapy for RRMM, offering differentiated efficacy with substantial safety management requirements.
Zolbetuximab establishes a targeted first-line treatment option for HER2-negative, CLDN18.2-positive gastric/GEJ adenocarcinoma, supported by pivotal efficacy and safety evidence.
COBENFY represents a novel non-dopaminergic antipsychotic for schizophrenia, demonstrating consistent monotherapy efficacy with differentiated tolerability and selective clinical positioning.
177Lu-DOTATATE is a well-established, cost-effective targeted radioligand therapy positioned for SSTR-positive GEP-NETs requiring specialized, multidisciplinary care.
Daratumumab improves multiple myeloma outcomes across disease stages, with manageable toxicity, operational advantages in subcutaneous delivery, and expanding guideline-supported roles.